For Clinicians
Societi is a very new organisation – we celebrated our first birthday in December 2016. As we grow over time, we will extend this section of our website to include more resources, information and downloadable documents – as well as links to other useful websites.
If you’d like us to include your information on our website, links to relevant papers or articles, please contact us.
Learning information and resources for clinicians
TEMPERS! Awareness Raising Leaflet
We are working to make Kawasaki Disease memorable! Download our TEMPERS mnemonic and leaflet to help us do this - and raise awareness of Kawasaki Disease.
Re-THINK Kawasaki Disease – An Information Poster (Large Format)
We're determined to share as much information in every way we can - to build knowledge about Kawasaki Disease. Here's a HUGE poster (please print minimum A3 size) with LOADS of facts and figures.
NHS Improvement Service – Patient Safety Alert – Stage One Warning
This is a patient safety alert issued in May 2016 to all NHS Trusts in England. It asked for action from all providers of NHS funded care to assess and act on risks re failure to recognise acute coronary syndromes in Kawasaki Disease patients.
FOAM, Medical Education
This fantastic clinical learning resource (see link) has been shared with full consent of the patients family as obtained by the resource developers, ASKSNIFF who together with Dr Damian Roland (@Damian_Roland) have given Societi permission to provide a link here for clinicians visiting our site. Presenting Complaint: A 3 year old boy presents to an emergency department (ED) […]
Kawasaki Disease Research
Corticosteroid therapy in Kawasaki Disease
October 2017
This study suggests that corticosteroids combined with IVIG as initial therapy for KD showed a more protective effect against CAA, compared with conventional IVIG therapy, and the efficacy was more pronounced in the high-risk patient group.
Kawasaki Disease Increases the Incidence of Myopia
July 2017
The prevalence of myopia has rapidly increased in recent decades and has led to a considerable global public health concern.
Management of Kawasaki disease in adults
July 2017
Kawasaki disease is the most common childhood vasculitis in the USA and the most common cause of acquired cardiac disease in children in developed countries.
Dissecting Kawasaki disease: a state-of-the-art review
June 2017
Kawasaki disease (KD) is a pediatric vasculitis with coronary artery aneurysms (CAA) as its main complication.
Kawasaki Disease Management
Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki Disease: a meta-analysis.
This study compared the safety and efficacy of warfarin plus aspirin versus aspirin alone for the treatment of children with giant coronary artery aneurysm (CAA) secondary to Kawasaki Disease, and concluded that warfarin plus aspirin therapy reduced the incidence of occlusion, cardiac infarction and death in children with giant CAA secondary to Kawasaki Disease.
Failure to Predict High-Risk Kawasaki Disease Patients in a Population-Based Study Cohort in Germany. – PubMed – NCBI
This paper considers whether Kobayashi, Egami and Sano scores or application of up-to-date statistical methods (Random Forest) predict responses to standard IVIG therapy and the risk of persistent CAA in patients with KD in a mainly Caucasian population in Germany.
Retrospective study of the impact of unrecognised Kawasaki Disease, coronary aneurysm and ectasia
This is the first UK study to retrospectively review and characterise the angiographic prevalence of Kawasaki Disease. In doing so, both aneurysm and ectasia were observed with a relatively low frequency. However, their presence is associated with high-risk acute ischaemic presentations. A poor level of reporting of coronary abnormalities is reported and the authors advocate […]